Novartis’ Kisqali gains breakthrough status in premenopausal breast cancer
pharmafile | January 3, 2018 | News story | Research and Development, Sales and Marketing |Â Â Kisqali, Novartis, biotech, drugs, pharma, pharmaceuticalÂ
Novartis has received a major boost in its efforts to broaden use of its CDK4/6 inhibitor, by receiving a breakthrough status from the FDA in evaluating its potential for use in premenopausal women with breast cancer.
The announcement is significant because its product, Kisqali, currently lags behind the market leader, Pfizer’s Ibrance, but it is the first to receive the FDA’s attention in the premenopausal area. This could potentially open a much wider market for Kisqali, with the condition being the leading cause of cancer death in women between the ages of 20 and 59.
The designation is intended to expedite the development of medicine for conditions with serious unmet need, and will see a six-month review of the data compiled by Novartis.
Novartis applied to the FDA based on data from its Monaleesa-7 Phase 3 trial, which saw the treatment evaluated as a potential first line treatment for women with hormone-receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic disease, alongside tamoxifen or an aromatase inhibitor.
The study showed that Kisqali, in combination, was able to achieve median progression-free survival by 22.1 months compared with only 11 months when patients received oral endocrine therapies and goserelin.
“This Breakthrough Therapy designation reflects the significance and promise of the MONALEESA-7 data presented at SABCS last month,” said Samit Hirawat, Head of Novartis Oncology Global Drug Development. “Younger women often have distinct treatment goals and needs, and it is important for oncologists to offer effective and well-studied treatment options for their specific disease. We look forward to working with FDA to make this combination therapy available to premenopausal women living with HR+/HER2- advanced breast cancer in the US as soon as possible.”
Should Kisqali receive approval for the indication, it would go some way to improving its market share in comparison with Pfizer’s treatment. Ibrance is still some way in the lead after having reaped $2.4 billion in sales in the first three quarters of the year, with Novartis’ treatment only claiming single digit percentage of the overall CDK4/6 market.
Ben Hargreaves
Related Content
Pharma sees climate disruption as growing supply-chain risk
Nine in ten pharmaceutical companies across the UK and G7 countries expect climate-related disruption to …
AI in pharma: From lab development to patient impact
In the decade to 2025, AI use in vaccine development has increased markedly but is …
Scotland starts newborn screening for SMA
As part of a two-year evaluation funded by the Scottish government and Novartis, Scotland will …
